To evaluate the effectiveness of 2 artificial saliva formulations, sodium carboxymethylcellulose artificial saliva spray and sodium carboxymethylcellulose artificial saliva spray plus β-glucan.: This study was a double-blind randomized controlled trial and involved older adults with xerostomia. The xerostomia inventory score, clinical oral dryness score, oral moisture degree, unstimulated salivary flow rate, and salivary total antioxidant capacity were measured prior to and after treatment. The results were evaluated 4 weeks after taking both products. : The study included 51 subjects in the control (n = 25) and BG (n = 26) groups. xerostomia inventory score and clinical oral dryness score were significantly lower in both groups after 4 weeks of treatment (p<0.00). Additionally, both groups had significantly greater oral moisture degree and unstimulated salivary flow rate than before treatment (p<0.05). Only the increase in oral moisture degree in the BG group was significantly greater than that in the control group (p=0.048). Both groups tended to have decreased salivary total antioxidant capacity, but only the control group had a significant difference at 4 weeks (p=0.004). There was no significant difference in satisfaction score between the two groups. No serious side effects were found in the study. : The clinical signs and symptoms of xerostomia were improved by both control and artificial BG saliva. BG improved oral moisture more than the control. Furthermore, BG was more likely to prevent a decrease in salivary total antioxidant capacity than was the control.
15 March 2024 in Journal of Oral Medicine, Oral Surgery, Oral Pathology and Oral Radiology
Antibacterial and Antivirulence Effects of Kale (Brassica oleracea var. sabellica) on Streptococcus intermedius - JOOO- Print ISSN No: - 2395-6186 Online ISSN No:- 2395-6194 Article DOI No:- 10.18231/j.jooo.2024.007, Journal of Oral Medicine, Oral Surgery, Oral Pathology and Oral Radiology-J Oral Med Oral Surg Oral Pat
31 July 2026 in Natural and Life Sciences Communications
Recurrent Aphthous Stomatitis (RAS) is a common oral mucosal condition that adversely affects patients’ quality of life. Although its exact etiology remains unclear, current management primarily focuses on symptomatic relief and promotion of ulcer healing. This randomized, double-blind, controlled trial aimed to compare the clinical efficacy of HATAKABB® Anti-Cough Mouth Spray (HTK) with 0.1% Triamcinolone Acetonide Mouth Spray (TA) in patients with RAS. A total of 64 participants were randomly assigned to receive either HTK or TA three times daily for 7 days. Outcome measures included ulcer size, pain intensity assessed using a visual analog scale (VAS), healing time, and salivary tumor necrosis factor-alpha (TNF-α) levels, evaluated at baseline and after treatment. Baseline characteristics did not differ significantly between groups (P > 0.05). Both treatments resulted in significant reductions in ulcer size after 7 days (P < 0.001). Between-group comparison showed a greater reduction in ulcer size in the HTK group, and non-inferiority analysis confirmed that HTK was not inferior to TA in reducing ulcer size. No significant differences were observed between groups in healing time or VAS scores. Salivary TNF-α levels were significantly reduced in TA after treatment (P < 0.001), and the reduction in TNF-α (ΔTNF-α) was significantly greater in TA than HTK (P = 0.013), consistent with the known anti-inflammatory mechanism of corticosteroids. In conclusion, HTK may represent an effective non-steroidal topical alternative for reducing ulcer size in patients with RAS, particularly for individuals seeking options other than corticosteroid therapy.